Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Orenitram (treprostinil; United Therapeutics) Market Overview - Newer Brand Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) Poses Tough Competition in the Oral Prostacyclin Class | ||
By: PR Newswire Association LLC. - 27 Jun 2019 | Back to overview list |
|
DUBLIN, June 26, 2019 /PRNewswire/ -- The "Orenitram" report has been added to ResearchAndMarkets.com's offering. Orenitram (treprostinil; United Therapeutics) is a novel formulation of the prostacyclin analog treprostinil, formulated using Supernus Pharmaceuticals' drug delivery technology, allowing for twice-daily oral dosing. Orenitram represents the continuation of United Therapeutics' PH portfolio, led by intravenous Remodulin. Analyst Outlook Although Orenitram (treprostinil; United Therapeutics) was approved as the first oral prostacyclin analog in the US, addressing an important unmet need of the time, its clinical data are weak and consequently the drug has only made a minor impact on the pulmonary hypertension (PH) market.
LIST OF FIGURES
LIST OF TABLES
For more information about this report visit https://www.researchandmarkets.com/r/r60irq Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. Media Contact: Research and Markets SOURCE Research and Markets |
||
|
||
Copyright 2019 PR Newswire Association LLC. | Back to overview list |